References
- US Food and Drug Administration. Real-world evidence. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed July 7, 2020.
- Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297. doi:10.1056/NEJMsb1609216
- McConnell MV, Shcherbina A, Pavlovic A, et al. Feasibility of obtaining measures of lifestyle from a smartphone app: the Myheart Counts Cardiovascular Health study. JAMA Cardiol. 2017;2(1):67–76. doi:10.1001/jamacardio.2016.4395
- US Congress. 21st Century Cures Act. H.R. 34. Available from: https://www.congress.gov/114/bills/hr34/BILLS-114hr34enr.pdf. Accessed July 7, 2020.
- Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2019. doi:10.1002/pds.4932
- Cleary M. Artificial intelligence: the key to unlocking novel real-world data? Value Outcomes Spotlight. 2019;5(2):16–19.
- Khera R, Krumholz HM. With great power comes great responsibility: big data research from the national inpatient sample. Circ Cardiovasc Qual Outcomes. 2017;10:7. doi:10.1161/CIRCOUTCOMES.117.003846
- Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304. doi:10.2147/JMDH.S160029
- Matheny M, Israni ST, Ahmed M, Whicher D, editors. Artificial Intelligence in Health Care: The Hope, the Hype, the Promise, the Peril. Washington, DC: National Academy of Medicine; 2019.
- US Food and Drug Administration. PDUFA VI: fiscal years 2018-2022. Available from: https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vi-fiscal-years-20182022. Accessed July 7, 2020.
- Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674–678. doi:10.1056/NEJMsb1901642
- Alemayehu D, Cappeleri JC, Emir B, Zou KH, editors. Statistical Topics in Health Economics and Outcomes Research. Boca Raton, FL Chapman and Hall/CRC Press; 2017.
- Chambers RB, Zou KH, Nakazuru Y, et al. RWE for lorazepam IV regulatory approval in Japan. Presented at Joint Statistical Meeting, Denver,CO; 2019.
- Gottlieb S. Harnessing real world evidence for safety and innovation. https://www.fda.gov/news-events/speeches-fda-officials/harnessing-real-world-evidence-safety-and-innovation-11192018. Accessed July 7, 2020.
- US Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff. Docket no. FDA-2016-D-2153. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices. Accessed July 7, 2020.
- US Food and Drug Administration. Use of electronic health record data in clinical investigations: guidance for industry. Docket no. FDA-2016-D-1224. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry. Accessed July 7, 2020.
- US Food and Drug Administration. Framework for FDA’s real-world evidence program. Available from: https://www.fda.gov/media/120060/download. Accessed July 7, 2020.
- US Food and Drug Administration. Submitting documents using real-world data and real-world evidence to FDA for drugs and biologics: guidance for industry. Docket no. 2019-09529. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drugs-and-biologics-guidance. Accessed July 7, 2020.
- European Medicines Agency. Regulatory perspective on real world evidence (RWE) in scientific advice. EMA human scientific committees’ working parties with patients’ and consumers’ organisations (PCWP) and healthcare professionals’ organisations (HCPWP). Available from: https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-real-world-evidence-rwe-scientific-advice-emas-pcwp-hcpwp-joint_en.pdf. Accessed July 7, 2020.
- Center for Drug Evaluation (China). Key Considerations in Using Real-World Evidence to Support Drug Development. NMPA; 2019.
- Adding real-world evidence to a totality of evidence approach for evaluating marketed product effectiveness. Available from: https://healthpolicy.duke.edu/sites/default/files/u31/totality_of_evidence_appendix.pdf. Accessed Jly 7, 2020.
- Wedam S, Fashoyin-Aje L, Bloomquist E, et al. FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin Cancer Res. 2020;26(6):1208–1212. doi:10.1158/1078-0432.CCR-19-2580
- Deloitte. Getting real with real-world evidence (RWE) 2017 RWE benchmark survey. Available from: https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/real-world-evidence-benchmarking-survey.html. Accessed July 7, 2020.
- Davis B, Morgan J, Shah S. The future of real-world evidence Biopharma companies focus on end-to-end, AI-driven, internally developed solutions. Available from: https://www2.deloitte.com/us/en/insights/industry/life-sciences/2018-real-world-evidence-benchmarking.html?id=gx:2sm:3tw:4RWE_LSHC18::6Life_Sciences_and_Healthcare:20180711095200:Global&linkId=54041116. Accessed July 7, 2020.
- Morgan J, Feghali K, Shah S, Miranda W. RWE focus is shifting to R&D, early investments begin to pay off. Available from: https://www2.deloitte.com/us/en/insights/industry/health-care/real-world-evidence-study.html?id=us:2sm:3li:4di_gl:5eng:6di. Accessed July 7, 2020.
- Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574–578.
- Hripcsak G, Ryan PB, Duke JD, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329–7336. doi:10.1073/pnas.1510502113
- Hernandez-Boussard T, Monda KL, Crespo BC, Riskin D. Real world evidence in cardiovascular medicine: ensuring data validity in electronic health record-based studies. J Am Med Inform Assoc. 2019;26(11):1189–1194. doi:10.1093/jamia/ocz119
- Shaw R. The 10 best machine learning algorithms for data science beginners. Available from: https://www.dataquest.io/blog/top-10-machine-learning-algorithms-for-beginners/. Accessed July 7, 2020.
- Shah P, Kendall F, Khozin S, et al. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit Med. 2019;2:69. doi:10.1038/s41746-019-0148-3
- Xie H. Robotic process automation in healthcare will lead to better patient outcomes. In: Information Age. Bonhill Group Plc; 2019.
- Dietz R, Raimondo C, Kremer J, Reynolds J, Saxena R. Robotics in Claims: Transformation Through Intelligent Automation. Ernst & Young LLP; 2018.
- Association for Intelligent Information Management. Intelligent information management glossary: what is robotic process automation? Available from: https://www.aiim.org/What-is-Robotic-Process-Automation#. Accessed July 7, 2020.
- Juhn Y, Liu H. Natural language processing to advance EHR-based clinical research in allergy, asthma, and immunology. J Allergy Clin Immunol. 2020;145(2):463–469. doi:10.1016/j.jaci.2019.12.897
- Lin H, Long E, Ding X, et al. Prediction of myopia development among Chinese school-aged children using refraction data from electronic medical records: A retrospective, multicentre machine learning study. PLoS Med. 2018;15(11):e1002674. doi:10.1371/journal.pmed.1002674
- Kiely DG, Doyle O, Drage E, et al. Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulm Circ. 2019;9(4):2045894019890549. doi:10.1177/2045894019890549
- Blaivas M, Blaivas L. Are all deep learning architectures alike for point-of-care ultrasound?: evidence from a cardiac image classification model suggests otherwise. J Ultrasound Med. 2020;39(6):1187–1194. doi:10.1002/jum.15206
- Mahajan V, Venugopal VK, Murugavel M, Mahajan H. The algorithmic audit: working with vendors to validate radiology-ai algorithms-how we do it. Acad Radiol. 2020;27(1):132–135. doi:10.1016/j.acra.2019.09.009
- European Commission. Communication from the Commission to the European Parliament and the Council: Data Protection Rules as a Trust-Enabler in the EU and Beyond Taking Stock. Brussels, Belgium. 2019.
- Hu K, LaFontaine P, Mandic A, et al. An assessment of real-world data, artificial intelligence, and their use in drug development. Presented at Drug Information Association; February 57, 2019; Vienna, Austria.
- American Statistical Association. Statistical Partnerships Among Academe, Industry, and Government (SPAIG) award. Available from: https://www.amstat.org/ASA/Your-Career/Awards/Statistical-Partnerships-Among-Academe-Industry-and-Government-Award.aspx. Accessed July 7, 2020.
- Rizvi S, Majumdar M, Zou KH, Ray A. Partnerships in action: advancing healthcare through collaborative science in emerging markets. Available from: https://www.cioapplications.com/cxoinsights/partnerships-in-action-advancing-healthcare-through-collaborative-science-in-emerging-markets-nid-5717.html. Accessed July 7, 2020.
- Ali R, El Shahawy O, Zou KH, Sherman S, Weitzman M, Ray A. NYU Abu Dhabi and Pfizer Inc. collaboration drives progress. Available from: https://magazine.amstat.org/blog/2020/04/01/nyu-abu-dhabi-pfizer/. Accessed July 7, 2020.
- Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand SL. Prospective observational studies to assess comparative effectiveness: the ISPOR Good Research Practices Task Force Report. Value Health. 2012;15:217–230. doi:10.1016/j.jval.2011.12.010
- Zou KH, Imperato J, Ovalle JC, Li JZ, Sethi N, Ray A. Enhanced patient-centricity: optimizing patient care through AI/ML/DL. PharmaVoice. 2020;20(6):52–54.